ELECTION 2012

Election Ballots must be received at ASPET by 5:00 pm EST on January 27, 2012

Online Election Ballot will close at 5:00 pm EST on January 27, 2012

AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
9650 Rockville Pike, Bethesda, Maryland 20814-3995 ✖ 301-634-7060 ✖ 301-634-7061 fax
info@aspet.org www.aspet.org

ASPET Election 2012 Candidates

Ballots due 5:00 pm on January 27, 2012

NOMINEES FOR ASPET OFFICE

NOMINEES FOR PRESIDENT-ELECT

Bryan F. Cox
Richard R. Neubig

NOMINEES FOR SECRETARY/TREASURER-ELECT

Carol A. Paronis
Sandra P. Welch

NOMINEES FOR COUNCILOR

Charles P. France
Haian Fu

NOMINEES FOR DIVISION OFFICE

DIVISION FOR DRUG METABOLISM

Nominees for Chair-Elect

John Y. Chiang
Jeffrey P. Jones
Wen Xie

Nominees for Secretary/Treasurer-Elect

Nina Isoherranen
Xiao-bo Zhang

DIVISION FOR MOLECULAR PHARMACOLOGY

Nominees for Chair-Elect

John J. Tesmer
Guangyu Wu

Nominees for Secretary/Treasurer-Elect

Rennolds S. Ostrom
Yaping Tu

DIVISION FOR INTEGRATIVE SYSTEMS, TRANSLATIONAL AND CLINICAL PHARMACOLOGY

Nominee for Chair-Elect

Ismail Laher

Nominee for Secretary/Treasurer-Elect

Michael A. Holinstat

DIVISION FOR NEUROPHARMACOLOGY

Nominee for Chair-Elect

Anne M. Andrews
Laura M. Bohn

Nominees for Secretary/Treasurer-Elect

Lakshmi A. Devi
Susan L. Ingram Osborn
Ping-yee Law

DIVISION FOR TOXICOLOGY

Nominees for Chair-Elect

Rick G. Schnellmann
Jeffrey Staudinger

Nominees for Secretary/Treasurer-Elect

Laura James
Kenneth E. McMartin

NO ELECTIONS THIS YEAR FOR:
Division for Behavioral Pharmacology
Division for Cardiovascular Pharmacology
Division for Drug Discovery, Development & Regulatory Affairs
Division for Pharmacology Education

Nominees for ASPET Office

NOMINEE FOR PRESIDENT-ELECT

BRYAN F. COX

Director, Integrative Pharmacology, Global Pharmaceutical Research and Development and Head, Renal Discovery, Abbott Laboratories, Abbott Park, Illinois

Education: B.S. (1983, Biological Sciences), North Carolina State University; Ph.D. (1987, Pharmacology), University of Iowa, Iowa City, IA.

Professional Experience:

- Postdoctoral Fellow (1988-1990), Department of Pharmacology, University of Texas Health Science Center at San Antonio.
- Research Scientist (1990-1991), Senior Research Scientist (1991-1993), Associate Research Fellow (1993-1996), Rhône-Poulenc Rorer, Inc.
- Senior Group Leader (1996-2000), Project Leader/Department Manager (2000-2001), Senior Project Leader/Department Manager (2001-2003) Director (2003-present), Integrative Pharmacology, Abbott Laboratories.
- Head (2009-present), Renal Discovery, Abbott Laboratories.

Research Interests; Integrative Pharmacology has core expertise in cardiovascular, renal, gastrointestinal and respiratory pharmacology as well as cardiac electrophysiology. Translational Imaging uses MRI, PET/CT and SPECT/CT to answer pivotal questions for the Oncology and Neuroscience Therapeutic Areas. Dr. Cox served as Discovery Representative on a number of committees, including: the Vascular Medicine Franchise Leadership Team which was responsible for developing the strategic plan for the Vascular Medicine Business Unit.; the Collaborative Research and Development Committee which worked on diabetic neuropathy in collaboration with the Hungarian firm, Biorex; and the Acute Care, Dislipidemia, and Renal Therapeutic Area Executive Committees with responsibility for integration of discovery, development, commercialization and regulatory affairs across the disease areas.

Dr. Cox has been a member of ASPET since 1994. He is currently the Past Secretary/Treasurer, having served as Secretary/Treasurer in 2010-2011. He was a charter member of the Executive Committee of the Drug Discovery, Drug Development and Regulatory Affairs Division from 2000 – 2005 and served as Chair-elect, Chair and Past Chair from 2000-2003. From 1999-2003 he was a member of the ASPET Program Committee. Dr. Cox has been a member of the Editorial Board of the *Journal for Pharmacology and Experimental Therapeutics* since 2000 and of *Molecular Interventions* since 2005. He was elected to a three-year term as ASPET Councilor in 2005. As Councilor he served on the Editorial Advisory Board of *The Pharmacologist*, as Council liaison to the Division for Cardiovascular Pharmacology and the Division for Systems and Integrative Pharmacology, as a member of the Long Range Planning Committee, and as chair of the ASPET Awards Committee. He was also a member of the Astellas Awards Committee. As Secretary/Treasurer, Dr. Cox is a member the Finance Committee (chair in 2010-2011) and the Investment Committee. He serves as Council liaison to the Diversity Committee and the Division for Drug Discovery, Development and Regulatory Affairs. Dr. Cox is also a member of the American

Heart Association, the American Physiological Society, Phi Eta Sigma National Honor Society, and the International Society for Magnetic Resonance in Medicine.

Candidate's Statement:
Some would argue that these are difficult times for the discipline of Pharmacology. It is true that Federal/State budgets are under pressure. There have been major consolidations in the Pharmaceutical industry. Venture Capital has been difficult for Biotechnology companies to obtain.

However, I would argue that Pharmacology is headed into unprecedented opportunity. Never has there been such a collaborative spirit between Academia and Industry. Every major Pharma has Scouts actively seeking to collaborate on areas of mutual interest. New technologies allow us to ask and answer key/fundamental questions more quickly than ever before. There is a vigorous interest in translating basic pharmacologic discoveries into useful therapeutics.

The American Society for Pharmacology and Experimental Therapeutics is a critically important organization for both addressing our challenges and exploiting our opportunities. The Division structure allows ASPET to rapidly respond to changes in Pharmacology. Public Affairs gives us a voice in important discussions. The annual meeting continues to have excellent content. The Journals are an important medium for conveying key findings to a broad audience.

As we go forward, it will be important for the Society to build on this strong foundation. We need to continue to provide students not only with excellent training, but to also inform them about the variety of career options available to pharmacologists. Intellectual property law, Regulatory Affairs, Clinical Sciences Monitors, teaching/research at Colleges and Universities without a Department of Pharmacology – there are an array of opportunities available to a well-trained pharmacologist.

In closing, pharmacology as a discipline filled with opportunity. Independent of the place at which we work, the need of patients will remain great. New discoveries will lead us to novel therapeutics to meet those unmet medical needs.

NOMINEE FOR PRESIDENT-ELECT

RICHARD R. NEUBIG

Professor, Department of Pharmacology, The University of Michigan, Ann Arbor, Michigan

Education: B.S. (1975, Chemistry), University of Michigan, Ann Arbor, MI; M.D./Ph.D. (1981, Pharmacology), Harvard University/Harvard Medical School, Boston, MA.

Professional Experience:
- House Officer (1981-1984), Department of Internal Medicine, University Hospital, Ann Arbor, MI.
- Instructor (1983-1984), Assistant Professor (1984-1989), Associate Professor (1989-1994), Professor (1994-present), Department of Pharmacology, Assistant Professor (1984-1989),

Associate Professor (1990-present), Department of Internal Medicine, Co-Director (2004-present), Center for Chemical Genomics, The University of Michigan, Ann Arbor, MI.

Research Interests: Our laboratory studies molecular, cellular, and physiological aspects of signaling by guanine nucleotide binding proteins (G proteins) and G protein coupled receptors (GPCRs). Recent efforts have also focused on a program of academic drug discovery. While GPCRs are the target of nearly half of current drugs on the market, most studies narrowly focus on ligands targeting the receptor binding site. Recent developments make it clear that classical linear models of GPCR signaling are oversimplified and that signaling involves complex networks of interacting targeting and regulatory proteins. For the last 10-15 years, we have focused on the mechanism, function, and pharmacological targeting of the Regulators of G protein Signaling (RGS proteins). In a 2001 review article in *JPET*, we first outlined the background and rationale for targeting RGS proteins pharmacologically. Blocking their negative actions on G proteins would enhance GPCR agonist function. More interestingly, it could improve the specificity of agonist signaling by selectively enhancing it in a tissue- or pathway-specific manner. In a two-pronged approach to this question we have developed both mutant animal models (RGS-insensitive G protein knock-ins) to address the physiological roles of RGS proteins and RGS inhibitor chemical probes to demonstrate druggability. Our mouse models show strong and important phenotypes (antidepressant-like effects, reduced weight gain on high-fat diets, and reduced cardiac ischemia/reperfusion injury). We have also successfully discovered small molecules targeting the challenging RGS/Gα subunit protein-protein interaction. Most recently, we have demonstrated enhanced cardiac muscarinic receptor signaling *in vivo* with RGS inhibitor treatment. Future plans include further improvements in our RGS inhibitor molecules as well as mechanistic studies with conditional knock-in mice to further validate RGS proteins as novel drug targets. A long term goal is to prove the principle of RGS proteins as viable drug targets and to see RGS modulator drugs ultimately move into therapeutic use.

Dr. Neubig has been a member of ASPET since 1987. He was the founding Chair of the Molecular Pharmacology Section from 1994-1997. He played a key role in the retreat which recommended the creation of divisions and conversion of the existing sections into divisions. Dr. Neubig remained as Chair to oversee the transition of the section to the Division for Molecular Pharmacology (1997-1999) and then remained on the Executive Committee until 2002. During that period (1997-2000)he served on the Scientific Council (now Council of Division Chairs). Dr. Neubig was a member of the ASPET Scientific Program Committee for the 2002 IUPHAR meeting in San Francisco. He served on the Membership Advisory Committee from 1999-2001 and the Goodman and Gilman Award Committee from 2002-2005. He was elected Councilor in 2009 and as senior Councilor, serves as chair of the ASPET Awards Committee for 2011-2012. Dr. Neubig has served on the Editorial Board of *Molecular Pharmacology* since 1992 and from 1996 to 2000 was an Associate Editor for that journal. Most recently he was a member of the Editorial Advisory Board of *Molecular Interventions.* He also served on the Board of Publications Trustees from 2004-2008. Dr. Neubig represents ASPET on the IUPHAR Nominating Committee. He has organized several symposia, workshops and colloquia for the ASPET Annual Meeting. In 2009 he was the recipient of the ASPET-Astellas Award for Translational Pharmacology. Dr. Neubig is also a member of the AAAS, the Biophysical Society, and the American Society for Biochemistry and Molecular Biology.

Candidate's Statement

This is an exciting time for pharmacology and therapeutics and our society, ASPET. Tremendous advances in the molecular understanding of basic physiological processes, drug and disease mechanisms, toxicology, and pharmacogenomics provide huge opportunities to improve the treatment of human diseases. At the same time, there are major changes in environment for the field of pharmacology and ASPET; our members must understand them and efficiently adapt. The role of pharmacology departments in the traditional setting of medical schools and other professional schools is changing. Our members and partners in the pharmaceutical industry are also experiencing major readjustments. The push for translational research at NIH and other funding agencies is a ripe opportunity for ASPET members but scientists from other disciplines are also moving aggressively into therapeutics. The emerging field of chemical biology, with chemists and biochemists undertaking

biological and pharmacological studies, is tackling problems traditionally in the realm of molecular pharmacology. The advent of macromolecular therapeutics (i.e. biologicals and nucleotide therapeutics), as well as regenerative medicine, is markedly altering the scope of drug discovery, development, and clinical treatments.
To thrive in this exciting but challenging landscape, it is critical for ASPET to maintain its strength in the basic understanding of drug and disease mechanisms but we must also embrace these exciting new developments. In addition to presenting the best science on drug mechanisms, therapeutics, and drug discovery at our annual meetings, we should engage – and ultimately bring to our society membership - these new groups that are redefining drug discovery. Scientists attacking basic pharmacology or therapeutics questions from the arenas of chemical biology, structure-based drug design, computational and systems biology and bioinformatics, iPSCs, and regenerative medicine should be included at meetings and encouraged to join ASPET. The outstanding work by our Divisions to build communities and to provide strong programming would make them the optimal locus of active efforts to expand our society in this way.

The major rearrangements in the pharmaceutical sector, with significant shifting of basic drug discovery research toward academic and start-up organizations, also represent an important opportunity for ASPET members. Ensuring strong communication with pharmaceutical scientists, in part through the Drug Discovery, Development and Regulatory Affairs Division, will be critical. This could include providing networking opportunities for members from commercial and academic institutions as well as programming at the annual meeting to inform both groups of the needs and capabilities of each.

Another major mission of ASPET is the teaching of pharmacology and therapeutics. As many medical schools dial back the amount of didactic basic science teaching, we should foster opportunities to ensure that budding physicians and other health professionals receive a strong background in our discipline. Two opportunities are undergraduate teaching and classes during the clinical years for health professionals. We should capitalize on efforts of the Division for Pharmacology Education as well as the numerous programs that have built strong undergraduate pharmacology classes. Providing teaching tools and actively sharing curriculum ideas would facilitate exposure of undergraduate students to Pharmacology. Also, programs such as the Zannoni Summer Undergraduate Research Fellowships provide one important venue for engaging undergraduates to enhance the pipeline of new scientists for our discipline.
ASPET should strive to be the primary driver of advances in pharmacology and therapeutics. This will require that we actively engage and provide for our membership the best and most up-to-date science in this area. By incorporating scientists, members and non-members, who are at the forefront of new models of therapeutics we can both expand our community and ensure that ASPET represents the cutting edge of the discipline.

It would be an honor to serve as the President of ASPET. I look forward to the opportunity to work closely with our outstanding membership, divisions, and journals and to further enrich them with the exciting new opportunities that await.

NOMINEE FOR SECRETARY/TREASURER-ELECT

CAROL A. PARONIS

Assistant Professor, Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts

Education: B.S. (1985), Tufts University; Ph.D. (1993, Pharmacology), Emory University, Atlanta,GA.

Professional Experience:

- Postdoctoral Fellow (1993-1996), Department of Pharmacology, University of Michigan
- Postdoctoral Fellow in Psychobiology(1996-1997), New England Regional Primate Center, Harvard Medical School
- Research Associate in Psychiatry (1996-1997), McLean Hospital, Belmont, MA
- Instructor in Psychobiology (1997-2002), Assistant Professor of Psychobiology (2002-2008), Department of Psychiatry, Harvard Medical School
- Assistant Professor (2008-present), Department of Pharmaceutical Sciences, Northeastern University School of Pharmacy, Boston, MA

Research Interests: Dr Paronis specializes in studying abused substances and therapeutic drugs *in vivo* using both behavioral and physiological endpoints. She has been especially interested in pharmacological and behavioral mechanisms that contribute to changes in drug sensitivity resulting from chronic drug exposure. Dr. Paronis has conducted studies on the development of dependence and/or tolerance to ligands in several pharmacological classes, including cannabinoids, opioids, and benzodiazepines.

Dr. Paronis has been a member of ASPET since 1992. She was the Secretary/Treasurer of the Behavioral Pharmacology Division from 2002-2005 and a Councilor for the Division from 2005-2008. She has served as a judge for the Behavioral Pharmacology Division poster competition and initiated the Division's Meet and Greet Dinner for student and postdoctoral poster competitors. She is also a member of the Neuropharmacology Division. Dr. Paronis served on the ASPET Nominating Committee in 2003 and 2008. She has been a member of the Women in Pharmacology Committee since 2005 and its chair since 2008. She also served on the Web Advisory Committee from 2010-2011. Dr. Paronis represented ASPET on FASEB's Summer Research Conferences Advisory Committee from 2004-2005 and on FASEB's Excellence in Science Awards Committee since 2009. She has organized several short courses and symposia for the ASPET meeting. Dr. Paronis has received both Graduate Student and Young Scientist Travel Awards from ASPET since joining the Society as a student member in 1992.

NOMINEE FOR SECRETARY/TREASURER-ELECT

SANDRA P. WELCH

Professor, Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia

Education: B.S. (1971, Biology/Math), Dakota State College, Madison, South Dakota; M.S. (1973, Biology), University of North Dakota; Ph.D. (1986, Pharmacology/Toxicology), Virginia Commonwealth University, Richmond, VA.

Professional Experience:

- Chemist (1973-1976), Cargill, Inc. Seattle, WA
- Laboratory Specialist B (1976-1983), Postdoctoral Fellow (1986-1989), Affiliate Assistant Professor (1989-1990), Assistant Professor (1990-1994), Associate Professor (1994-1999), Professor (1999-present), Department of Pharmacology & Toxicology, Virginia Commonwealth University

Research Interests: Dr. Welch's research has focused on the mechanisms underlying nociception with emphasis on endogenous opioid/cannabinoid interactions using behavioral and biochemical methods. In addition, she has published on several chronic pain conditions and evaluated endogenous opioid tone in such states as arthritis and diabetic neuropathy. Her publications on cannabinoid/opioid interactions were among the first to directly link the two systems in the modulation of acute and chronic pain states. Her current funding is to determine the role of phospholipid mediators including sphingosine-1-phosphate in the modulation of opioid and cannabinoid analgesia. Love for teaching and training young scientists is also a priority for Dr. Welch. In addition to laboratory training, she teaches extensively in the professional and graduate schools of Virginia Commonwealth University and gives numerous community presentations on the risks of drugs of abuse.

Dr. Welch joined ASPET in 1991 as a student member. She was Secretary/Treasurer of the Neuropharmacology Division from 2004 – 2008. She is also a member of the Behavioral Pharmacology Division and the Division for Pharmacology Education. She has been a member of the *JPET* editorial board since 1993.

NOMINEE FOR COUNCILOR

CHARLES P. FRANCE

Professor Departments of Pharmacology and Psychiatry, the University of Texas Health Science Center at San Antonio, San Antonio, Texas

Education: B.A. (1977, Music), Northland College, Ashland, WI; M.A. (1984), Ph.D. (1985, Psychobiology), University of Michigan, Ann Arbor, MI.

Professional Experience:

- NIMH Research Fellow (1985-1987), Department of Psychiatry, Harvard Medical School
- Adjunct Assistant Professor, Department of Psychology, and Assistant Research Scientist, Department of Pharmacology (1987-1991), University of Michigan
- Associate Professor (1991-1994), Professor (1994-2000), Department of Pharmacology and Experimental Therapeutics, and Professor (1996-2000), Neuroscience Center of Excellence, Louisiana State University Medical Center at New Orleans
- Visiting Scientist (1998) Centre de Recherche Pierre Fabre, Castres, France
- Professor (2000-present), Departments of Pharmacology and Psychiatry, University of Texas Health Science Center at San Antonio

Research Interests: This laboratory investigates factors impacting the behavioral effects of drugs of abuse with a particular focus on drug interactions, dependence, withdrawal, and environmental factors (e.g., eating conditions) that modify drug effects. Three projects use a variety of behavioral procedures, including drug discrimination, self administration, delay discounting, conditioned place preference, and locomotion in several different species and these behavioral studies are augmented by physiological and neurochemical studies conducted with several collaborators. Opioids remain the drugs of choice for treating pain, but they are not effective under some conditions and they have well known adverse effects, including significant dependence and abuse liability. Our laboratory is testing the possibility that antinociceptive effects of opioids are enhanced by other drugs (e.g., cannabinoid receptor agonists and direct-acting serotonin receptor agonists) without increasing, and perhaps reducing, the abuse and dependence effects of opioids. Second, individuals who choose a smaller, immediately available reward, rather than wait for a larger reward, are said to be more impulsive and impulsivity is associated with increased risk of developing a substance abuse disorder. Our laboratory uses delay discounting procedures to examine the acute and chronic effects of drugs on this measure of impulsivity. Small doses of opioids increase impulsivity and those increases persist after discontinuation of drug treatment, suggesting that drug-induced impulsivity might contribute not only to ongoing drug abuse but also to other high-risk behavior long after drug use. Thus, impulsivity is not only a risk factor for developing a substance abuse disorder, but also a direct consequence of abusing some drugs. Third, changes in food intake can profoundly alter drug effects; for example, food restriction enhances drug self administration and eating high-fat food alters sensitivity to the behavioral and neurochemical effects of drugs acting on dopamine systems. Our studies explore the impact of food restriction, on one hand, and eating high-fat food, on the other, on the behavioral effects of drugs that are commonly used in the clinic or that are abused. These studies indicate that modest food restriction or eating high-fat food profoundly alter sensitivity to drugs and brain neurochemistry in a manner that could impact vulnerability to drug abuse as well as the therapeutic actions of drugs. Moreover, the impact of eating high fat food on sensitivity to indirect acting dopamine receptor agonists such as cocaine is greater in female rats than in male rats and is most evident during adolescence.

Dr. France has been a member of ASPET since 1992. He was Chair of the Behavioral Pharmacology Division from 2007-2009 and served on the Division Executive Committee from 2006-2010. He is also a member of the Neuropharmacology Division. He has organized numerous symposia and served as a member of the Program Committee from 2008-2010. He served on the Editorial Board of the *Journal for Pharmacology and Experimental Therapeutics* from 1997-2008. Dr. France has organized numerous events on behalf of ASPET including Volunteer Day with Habitat for Humanity in New Orleans in 2009 and the subsequent Volunteer Days that have become a tradition on the Friday preceding the ASPET Annual Meeting. In addition, he has organized recruitment receptions at the CPDD meetings in 2008 and 2009. Dr. France is also a member of the American College of Neuropsychopharmacology, Behavioral Pharmacology Society, College on Problems of Drug Dependence, European Behavioural Pharmacology Society, Society for Neuroscience, Society for Stimulus Properties of Drugs, Sigma Xi, and is a fellow of the American Psychological Association.

NOMINEE FOR COUNCILOR



HAIAN FU

Professor, Department of Pharmacology, and Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia

Education: B.S. (1982, Biology), Anhui University, Hefei, China;
Ph.D. (1989, Biochemistry), University of Wisconsin-Madison, Madison, WI.

Professional Experience:

- Postdoctoral Fellow (1989-1991), Instructor (1991-1994), Department of Microbiology & Molecular Genetics, Harvard Medical School.
- Assistant Professor (1994-2000), Associate Professor (2000-2006), Professor (2006-present), Department of Pharmacology, Professor (2006-present), Department of Hematology and Medical Oncology, Winship Cancer Center, Emory University.
- Molecular Discovery Director (2003-2004), Co-Director (2004-2010), Director (2010-present), Discovery and Developmental Therapeutics Program, Winship Cancer Institute of Emory University.
- Director (2003-present), Emory Chemical Biology Discovery Center, Co-Director (2004-present), Drug Development & Pharmacogenomics Academy, Emory University.

Research Interests: Dr. Fu's research focuses on protein-protein interactions in signal transduction pathways that control cell survival and death in normal and cancer cells. His team, in collaboration with chemists and physician scientists, targets protein interactions that are dysregulated in cancer for drug discovery and translational research. In his research, high-throughput screening technologies are used to identify small molecule modulators for pharmacological studies and therapeutic development.

Dr. Fu has been a member of ASPET since 1996. He is a member of the Molecular Pharmacology Division as well as the Integrative Systems, Translational and Clinical Pharmacology Division and the Drug Discovery, Development, & Regulatory Affairs Division. He has served on the ASPET Finance

Committee since 2007. He organized and chaired symposia for the ASPET meeting in 1999, 2004, 2006, and 2012., Dr. Fu was recently appointed an Associate Editor for *Molecular Pharmacology*.

Do Not Forget to Vote in Your Division Elections!

NO ELECTIONS THIS YEAR FOR:

Division for Behavioral Pharmacology
Division for Cardiovascular Pharmacology
Division for Drug Discovery, Development & Regulatory Affairs
Division for Pharmacology Education

CANDIDATES FOR DIVISION OFFICE

Division for Drug Metabolism

NOMINEE FOR CHAIR-ELECT
Division for Drug Metabolism

John Y. L. Chiang

Professor of Biochemistry and Molecular Pathology, Northeast Ohio Medical University (NEOMED), Rootstown, Ohio

Education: B.S. (1969, Agricultural Chemistry), National Taiwan University; Ph.D. (1976, Biochemistry), State University of New York at Albany.

Professional Experience: Postdoctoral Fellow (1976-1978), Department of Biological Chemistry, University of Michigan Medical School; Assistant Professor (1978-1983), Associate Professor (1983-1988), Professor (1988-present), Department of Biochemistry and Molecular Pathology, Northeastern Ohio Universities College of Medicine, now Northeast Ohio Medical University.

Research Interests: Dr. Chiang's laboratory purified and cloned the gene for cholesterol 7α-hydroxylase (CYP7A1), the first and rate-limiting enzyme in the bile acid biosynthetic pathway that converts cholesterol to bile acids. He has been studying the molecular mechanisms of bile acid-activated nuclear receptors FXR, PXR and VDR in regulation of bile acid, drug, lipid, glucose and energy metabolisms.

Activities:
ASPET: Member of ASPET since 1995. Divisions – Drug Metabolism (Secretary/Treasurer 2007-2008, Executive Committee 2006-2009), Cardiovascular Pharmacology, Molecular Pharmacology, Toxicology. Committees – ASPET Nominating Committee (1997).
Other: Member – AAAS, American Association for the Study of Liver Diseases, American Society for Biochemistry and Molecular Biology, Endocrine Society, International Society for the Study of Xenobiotics, Society of Chinese Bioscientists in America. Editorial Activities – Editorial Boards of *Journal of Biological Chemistry* and *Hepatology.*

NOMINEE FOR CHAIR-ELECT
Division for Drug Metabolism

Jeffrey P. Jones

Donald and Marianna Matteson Professor of Chemistry, Washington State University, Pullman, Washington

Education: B.S. (1982, Medicinal Chemistry), University of Michigan; Ph.D. (1987, Medicinal Chemistry), University of Washington, Seattle, WA.

Professional Experience: Postdoctoral Fellow (1987-1988), Department of Medicinal Chemistry, University of Washington; Postdoctoral Fellow (1988-1989), Department of Biochemistry, University of Wisconsin; Assistant Professor (1990-1996), Department of Pharmacology, Associate Professor of Pharmacology (1996-1998), Department of Pharmacology and Toxicology, Associate Professor of Biochemistry and Biophysics (1997-1998), Washington State University; Associate Professor of Chemistry (1998-2002), Professor (2002-present), Department of Chemistry, Washington State University, Donald And Marianna Matteson Professor of Chemistry (2008-present).

Research Interests: Dr. Jones' research interests are in understanding nitrogen-iron coordination effects on binding and metabolism by cytochrome P450 and structure-function and SNP characterization of human aldehyde oxidase.

Activities:
ASPET: Member of ASPET since 2007. Divisions – Drug Metabolism. Editorial Activities – Editorial Board for *Drug Metabolism and Disposition* (2003-present).
Other: Member – American Chemical Society, International Society for the Study of Xenobiotics. Co-inventor of human metabolism modeling licensed to Camitro Corp.

NOMINEE FOR CHAIR-ELECT
Division for Drug Metabolism

Wen Xie

Professor and Director, Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy and Professor, Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Education: M.D. (1991), Peking University Health Science Center; Ph.D. (1997, Cell Biology), University of Alabama at Birmingham.

Professional Experience: Postdoctoral Research Fellow (1998-2001), Howard Hughes Medical Institute, Salk Institute; Assistant Professor (2002-2006), Associate Professor (2007-2010), Professor (2011-present), Department of Pharmaceutical Sciences and Department of Pharmacology and Chemical Biology, University of Pittsburgh.

Research Interests: Dr. Xie's primary research interest is nuclear receptor-mediated transcriptional regulation of drug metabolizing enzymes and transporters, and the implications of this regulation in drug metabolism, physiology, and diseases. Dr. Xie's research is conducted using combinations of cell cultures and genetically engineered mice that include transgenic, knockout and humanized mice.

Activities:
ASPET: Member of ASPET since 2008. Divisions – Drug Metabolism (Early Career Achievement Award 2009); Molecular Pharmacology; Toxicology. Editorial Activities – *ad hoc* Reviewer for *Drug Metabolism and Disposition, JPET,* and *Molecular Pharmacology.*
Other: Member - ISSX (2008 James R. Gillette ISSX North American New Investigator Award); American Association for the Study of Liver Disease; Endocrine Society; Society of Toxicology. Editorial Activities - Editorial Board of *Current Drug Metabolism, Drug Metabolism Letters, Drug Metabolism Reviews, Molecular Endocrinology;* Guest Editor for *Current Drug Metabolism* (2005), *Advanced Drug Deliver Reviews* (2010), and *Drug Metabolism Reviews* (in progress); Editor, *Nuclear Receptors in Drug Metabolism* (Wiley).

NOMINEE FOR SECRETARY/TREASURER-ELECT
Division for Drug Metabolism

Nina Isoherranen

Assistant Professor of Pharmaceutics, School of Pharmacy
University of Washington, Seattle, Washington

Education: B.S (1998, Chemistry), M.S. (1998 Analytical Chemistry) University of Helsinki, Finland; Ph.D. (2003, Pharmaceutical Sciences) Hebrew University of Jerusalem, Israel.

Professional Experience: Postdoctoral Research Fellow (2003-2004), Acting Assistant Professor (2004-2006), Assistant Professor (2006-present), Department of Pharmaceutics, University of Washington.

Research Interests: Dr Isoherranen's main research interest is in understanding vitamin A disposition and metabolism by cytochrome P450 enzymes and xenobiotic CYP26 interactions. She is also conducting studies of in vitro-to-in vivo predictions of drug-drug interactions related to inhibitory metabolites and changes in drug metabolism and pharmacokinetics during pregnancy.

Activities:
ASPET: Member of ASPET since 2009. Divisions – Drug Metabolism; Integrative Systems, Translational and Clinical Pharmacology; Molecular Pharmacology; Toxicology

Other: Member – American Chemical Society, International Society for the Study of Xenobiotics, American Society for Mass Spectrometry.

NOMINEE FOR SECRETARY/TREASURER-ELECT
Division for Drug Metabolism



Xiao-bo Zhong

Associate Professor, Department of Pharmacology, Toxicology, & Therapeutics, University of Kansas Medical Center, Kansas City, Kansas

Education: Ph.D. (1998, Molecular Genetics), Wageningen University, The Netherlands.

Professional Experience: Postdoctoral Associate (1998-2001), Associate Research Scientist (2001-2004), Yale University School of Medicine; Assistant Professor (2004-2010), Associate Professor (2010-present), Department of Pharmacology, Toxicology, & Therapeutics, University of Kansas Medical Center.

Research Interests: Dr. Zhong's research is focused on pharmacogenomics, pharmacoepigenomics, and developmental pharmacology. His long-term research goals are to better understand how genetic polymorphisms and epigenetic alterations result in varied responses to drug metabolism.

Activities:
ASPET: Member of ASPET since 2007. Divisions – Drug Metabolism (Councilor 2009-present), Molecular Pharmacology. Editorial Activities: Ad hoc reviewer for *Drug Metabolism and Disposition*, *JPET*, and *Molecular Pharmacology*.
Others: Member - ISSX. Editorial Activities - Editorial Board Member of *Journal of Drug Metabolism and Toxicology, Frontiers in Pharmacogenetics* and *Pharmacogenomics.*

Division for Integrative Systems, Translational & Clinical Pharmacology

NOMINEE FOR CHAIR-ELECT
Division for Integrative Systems, Translational and Clinical Pharmacology



Ismail Laher

Professor, Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Education: B.Sc. (Hons, 1978) University of London, UK; M.Sc. (1980), Ph.D. (1983) University of British Columbia, Canada.

Professional Experience: Research Assistant Professor (1983-1995), Visiting Professor (2005-present), Department of Pharmacology, University of Vermont; Principal Scientific Officer (1991), University of Cape Town, South Africa; Assistant Professor (1995-2000), Associate Professor (2000-

2005), Professor (2005-present), University of British Columbia, Canada.

Research Interest: Endothelial dysfunction, oxidative stress in type 2 diabetes, resistance arteries, coronary and cerebral circulation, autoregulation, sleep apnea, stroke, exercise

Activities:
ASPET: Member of ASPET since 1988. Divisions – Integrative Systems, Translational and Clinical Pharmacology (Secretary/Treasurer of then SIP Division 2007-2009; Executive Committee 2009-present; Abstract Competition Committee 204-present); Cardiovascular Pharmacology; Pharmacology Education. Committees – Scientific Council (2004-2006), Program Committee (2007-2008), Nominating Committee (2008-2009).
Other: Member - The Microcirculatory Society, Canadian Society of Pharmacology and Therapeutics (Education Committee 2010-present), New England Smooth Muscle Society, South African Pharmacological Society. Editorial Activities – Editorial Boards of *Journal of Vascular Research, American Journal of Physiology (Heart and Circulatory Section),Advances in Pharmacology, World Diabetes Journal, World Journal of Cardiology, Frontiers in Cardiovascular and Smooth Muscle Pharmacology, Frontiers in the Pharmacology of Natural Products, CNS Neurosciences and Therapeutics, World Journal of Translational Medicine.*

NOMINEE FOR SECRETARY/TREASURER-ELECT

Division for Integrative Systems, Translational and Clinical Pharmacology

Michael A. Holinstat

Assistant Professor of Medicine and Biochemistry and Molecular Biology, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, Pennsylvania

Education: B.S. (1995, Biology), Southern Connecticut State University; M.S. (1999, Biological Sciences), University of Illinois, Chicago; Ph.D. (2004, Pharmacology), University of Illinois College of Medicine, Chicago, IL.

Professional Experience: Postdoctoral Research Fellow (2004-2008), Department of Pharmacology, Vanderbilt University; Assistant Professor (2008-Present), Medicine, Assistant Professor (2008-Present), Cardeza Foundation for Hematologic Research, Assistant Professor (2008-Present), Biochemistry and Molecular Biology, Thomas Jefferson University

Research Interest: My lab is focused on understanding the mechanisms by which 12-lipoxygenase (12-LOX) regulates platelet function and in turn thrombosis and hemostasis. The role of 12-LOX in regulating platelet reactivity, clot formation, and clot stability is not well understood and defining the role(s) of 12-LOX in the platelet may lead to the development of a novel anti-platelet therapy. Thus far, we have identified a number of regulatory roles for 12-LOX in the platelet and have recently collaborated on the development of the first small molecule inhibitor selectively targeting platelet-type 12-LOX. Additionally, my lab continues to study how thrombin regulates platelet function in a number of pathophysiological conditions including coronary artery disease and type II diabetes mellitus. By understanding how 12-LOX regulates platelet function, we may be able to develop a new approach to

treating over-active platelets which leads to a platelet clot and can eventually occlude the vessel and lead to stroke.

Activities:
ASPET: Member of ASPET since 2005. Divisions - Integrative Systems, Translational & Clinical Pharmacology, Cardiovascular Pharmacology, Molecular Pharmacology. Mid-Atlantic Pharmacology Society (MAPS - Councilor 2010-present). Awards – Graduate Student Travel Award (2002), Graduate Student Best Abtract in Molecular Pharmacology Award (2002), Young Scientist Best Abstract in Molecular Pharmacology Award (2008), Young Scientist Travel Award (2006, 2009)
Other: ASBMB (Membership Committee), American Society for Hematology, American Heart Association, International Society on Thrombosis and Haemostasis.

Division for Molecular Pharmacology

NOMINEE FOR CHAIR-ELECT
Division for Molecular Pharmacology

John J. Tesmer

Professor of Pharmacology and Research Professor of the Life Sciences Institute, University of Michigan, Ann Arbor, Michigan

Education: B.A. (1990, English and Biochemistry), Rice University; Ph.D. (1995, Biological Sciences), Purdue University, West Lafayette, IN.

Professional Experience: Post-doctoral Fellow (1996-1999), Department of Biochemistry, HHMI, University of Texas Southwestern Medical Center at Dallas; Assistant Professor (1999-2005), Department of Chemistry and Biochemistry, University of Texas at Austin; Associate Professor (2005-2011), Professor (2011-present), Department of Pharmacology, Research Associate Professor (2005-2011), Research Professor (2011-present), Life Sciences Institute, University of Michigan.

Research Interest: My lab studies the molecular basis of GPCR-mediated signal transduction, principally via the technique of X-ray crystallography. By determining atomic structures of signaling proteins alone and in complex with their various targets, we strive to provide important insights into the molecular basis of signal transduction and the disease states that emerge as a result of dysfunctional regulation of these pathways. We are also involved in the identification and structural characterization of novel therapeutic agents that modulate heterotrimeric G protein signaling.

Activities:
ASPET: Member of ASPET since 2006. Divisions – Molecular Pharmacology (Executive Committee 2009-present), Cardiovascular Pharmacology. Committees – ASPET Awards Committee (2010-present). Awards – 2009 John J. Abel Award
Other: Member - American Society for Biochemistry and Molecular Biology, American Crystallographic Association; Editorial Activities - Editorial Board of *Journal of Biological Chemistry;* Other - Chair, 2012 Gordon Research Conference on Phosphorylation and G Protein Mediated Signaling Networks.

NOMINEE FOR CHAIR-ELECT
Division for Molecular Pharmacology

Guangyu Wu

Associate Professor, Department of Pharmacology, Louisiana State University Health Sciences Center, New Orleans, Louisiana

Education: B.S. (1983, Biochemistry), Beijing Normal University; Ph.D. (1992, Physiology), Peking Union Medical College, Beijing, China.

Professional Experience: Postdoctoral Fellow (1995-1999), Dept of Cell and Molecular Pharmacology, Medical University of South Carolina; Assistant Professor Research (1999-2001), Dept of Internal Medicine, University of Cincinnati; Assistant Professor (2001-2006), Associate Professor (2006-present), Dept of Pharmacology, Louisiana State University Health Sciences Center; Professor (2011-), Dept of Pharmacology and Toxicology, Medical College of Georgia.

Research Interests: My current research focuses on the anterograde trafficking of G protein-coupled receptors (GPCRs) from the endoplasmic reticulum (ER) to the functional destinations. I am particularly interested in searching for motifs which dictate GPCR exit from intracellular compartments such as ER and Golgi and in defining the role of Ras-like small GTPases in the transport of nascent GPCRs along the secretory pathway.

Activities:
ASPET: Member of ASPET since 2002. Divisions – Molecular Pharmacology, Cardiovascular Pharmacology.
Other: Member – American Heart Association; American Society for Biochemistry and Molecular Biology; American Society for Cell Biology.

NOMINEE FOR SECRETARY/TREASURER-ELECT
Division for Molecular Pharmacology

Rennolds S. Ostrom

Associate Professor, Department of Pharmacology, University of Tennessee Health Science Center, Memphis, Tennessee

Education: B.A. (1990, Biology), Dartmouth College; Ph.D. (1998, Pharmacology and Toxicology), University of California, Irvine.

Professional Experience: Postdoctoral Fellow (1998-2001), Assistant Project Pharmacologist (2001-2003), Department of Pharmacology, University of California, San Diego; Assistant Professor (2003-2009), Associate Professor (2009-present) Department of Pharmacology, University of Tennessee Health Science Center.
Research Interests: Dr. Ostrom is interested in the molecular mechanisms of signal transduction by G protein-coupled receptors (GPCR) and their regulation of cellular function. His laboratory studies the compartmentation of GPCR and GPCR signaling components, particularly adenylyl cyclase (AC), in lipid rafts and caveolae. Dr. Ostrom studies the biochemical determinants of AC localization in lipid

rafts and seeks to understand the physiological effects of this compartmentation in cardiovascular and pulmonary cells.

Activities:
ASPET: Member of ASPET since 1999. Divisions – Molecular Pharmacology, Cardiovascular Pharmacology.
Other: AAAS; American Physiological Society, American Society for Biochemistry and Molecular Biology, Basic Cardiovascular Science Council of the American Heart Association.

NOMINEE FOR SECRETARY/TREASURER-ELECT

Division for Molecular Pharmacology

Yaping Tu

Associate Professor, Department of Pharmacology, Creighton University School of Medicine, Omaha, Nebraska

Education: B.S. (1987, Biochemistry), Wuhan University, China; Ph.D (1992, Molecular Biology and Biophysics), Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.

Professional Experience: Assistant Professor (1992), Associate Professor (1993), National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences; Postdoctoral Fellow/Instructor (1995-2000), Research Assistant Professor (2001-2003), Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas; Assistant Professor (2003-2007), Associate Professor (2008-present), Department of Pharmacology, Creighton University School of Medicine, Omaha, Nebraska

Research Interests: Molecular pharmacology of G protein-coupled receptors and RGS proteins. Current investigations focus on delineation of dysregulation of G protein-coupled receptor signal transduction by RGS proteins in human cancer development and progression using both cellular and murine models.

Activities:
ASPET: Member of ASPET since 2004. Divisions – Molecular Pharmacology (Executive Committee, 2010-present).
Other: Member – American Association for Cancer Research, *Biophysical Society* of China; Editorial Activities – Editorial Board of *Journal of Carcinogenesis* (2010-present), Editorial Board of *World Journal of Translational Medicine*(2011-present); Other - Creighton University Graduate School Board (2008-present).

Division for Neuropharmacology

NOMINEE FOR CHAIR-ELECT
Division for Neuropharmacology

Anne M. Andrews

Professor of Psychiatry, Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, California

Education: B.S. (1985, Chemistry/Russian Area Studies minor,) Pennsylvania State University; Ph.D. (1993, Chemistry) American University, Washington, DC; Thesis research, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.

Professional Experience: Postdoctoral fellow (1993–1997), Senior Staff Fellow (1998), Section on Clinical Neuropharmacology, Laboratory of Clinical Science, National Institute of Mental Health, National Institutes of Health; Assistant Professor of Chemistry (1998-2004) Department of Chemistry, Assistant Professor of Molecular Toxicology (2005-2007), Associate Professor of Molecular Toxicology (2007-2010), Adjunct Professor of Molecular Toxicology (2010-present) Department of Veterinary & Biomedical Sciences, Pennsylvania State University; Adjunct Professor of Chemistry (2008-2010), Department of Chemistry, Pennsylvania State University;
Member (2009-present) California NanoSystems Institute, University of California, Los Angeles; Senior Research Scientist (2009-present) Hatos Center for Neuropharmacology, University of California, Los Angeles.

Research Interest: Andrews' group research is centered on understanding how the serotonin neurotransmitter system modulates complex behaviors including anxiety, mood, stress responsiveness, and learning and memory. The expression and function of the serotonin transporter is studied in peripheral blood cells and lymphoblast cell lines from human and nonhuman primates, and in genetic and pharmacologic mouse models. Therapeutics, drugs of abuse, neurotoxins, and environmental factors are used to probe the molecular basis of serotonin system function associated with the etiology and treatment of mood and anxiety disorders and predictive personalized medicine.

Activities:
ASPET: Member of ASPET since 2011. Divisions – Neuropharmacology, Behavioral Pharmacology, Molecular Pharmacology.
Other: Member - American Chemical Society, Collegium Internationale Neuropsychopharmacologicum (elected fellow), Serotonin Club (elected councilor), Sigma Xi Scientific Research Society, Society for Electroanalytical Chemistry, Society for Neuroscience.
Editorial Activities - Associate Editor (2012) ACS Chemical Neuroscience.

NOMINEE FOR CHAIR-ELECT

Division for Neuropharmacology

Laura M. Bohn

Associate Professor with Tenure, Departments of Molecular Therapeutics and Neuroscience, The Scripps Research Institute, Jupiter, Florida

Education: B.S. (1993, Biochemistry), B.A. (1993, Chemistry), Virginia Tech; Ph.D. (1999, Biochemistry and Molecular Biology), Saint Louis University School of Medicine, St.Louis, MO.

Professional Experience: Postdoctoral Fellow (1999-2002) Cell Biology/ HHMI, Assistant Research Professor (2002-2003) Cell Biology, Duke University Medical Center; Assistant Professor (2003-2007), Associate Professor with tenure (2007-2009) Pharmacology & Psychiatry, The Ohio State University College of Medicine; Associate Professor with tenure (2009-current) Molecular Therapeutics & Neuroscience, The Scripps Research Institute, Scripps Florida

Research Interest: Dr. Bohn's research is focused upon understanding how regulation of G protein-coupled receptors can ultimately determine the extent of drug responsiveness in vivo. By seeking an understanding how receptors function in their endogenous neuronal settings, the Bohn lab hopes use this information to direct the generation of receptor ligands that may allow for the differentiation of preferential signaling pathways (therapeutic efficacy) over undesirable signaling pathways (side effects). The neurotransmitter systems of most interest to the Bohn lab focus upon the neuropharmacology of serotonin and opioid receptors.

Activities:
ASPET: Member of ASPET since 2004. Divisions – Neuropharmacology (Executive Committee 2010-present; Best Abstract Competition Judge 2011), Behavioral, Molecular Pharmacology. Editorial Activities – Editorial Board Mini-Review Editor, *Molecular Pharmacology*(2010-present). Awards – 2011 John J. Abel Award. Other – 4th GPCR Colloquium organizer (2013)
Other: Member – College on Problems of Drug Dependence, International Narcotics Research Conference (INRC) (Program Committee), Society for Neuroscience (Minisymposium organizer 2005). Editorial Activities – Editorial Board for *Life Sciences* (2006-present). Other - Janssen Pharmaceutica/ Discovery International Speakers Bureau (2004-2006), AAPS/ NIDA Frontiers: Drug Addiction- From Basic Research to Therapies (Organizational Committee 2004), Scientific Advisory Board for Mencuro Therapeutics, Inc. (Co-founder and Director).

NOMINEE FOR SECRETARY/TREASURER-ELECT
Division for Neuropharmacology

Lakshmi A. Devi

Professor, Department of Pharmacology and Systems Therapeutics, Department of Psychiatry, and Department of Neuroscience, and Associate Dean for Academic Enhancement and Mentoring, Mount Sinai School of Medicine, New York, New York

Education: B.Sc. (1974, Biology), M.Sc. (1976, Botany), University of Mysore, Karnataka, India; Ph.D. (1982, Biology), University of Windsor, Ontario, Canada.

Professional Experience: Postdoctoral fellow (1982-1984), Addiction Research Foundation, Palo Alto, CA; Postdoctoral Research Associate (1985-1986),The Vollum Institute, Portland, OR; Assistant Professor (1987-1995), Associate Professor (1996-2002), Department of Pharmacology, NYU School of Medicine; Professor (2002-present), Department of Pharmacology and Systems Therapeutics, Professor (2005-present), Department of Psychiatry, Director (2006-2008), Office of the Postdoctoral Affairs, Director (2007-present), Postdoctoral Training Program in Drug Abuse Research, Associate Dean for Academic Enhancement and Mentoring (2008-present), Professor (2010-present), Department of Neuroscience, Mount Sinai School of Medicine.

Research Interest:
1. Molecular Mechanisms of G Protein-Coupled Receptor Signaling in Disease
2. Neuroproteomics of the Synapse and Drug-induced Changes in Signaling Networks
3. Identification and Characterization of Novel Neuropeptides and their Receptors

Activities:
ASPET: Member of ASPET since 1999. Divisions – Neuropharmacology, Molecular Pharmacology.
Other: Member – AAAS, American Society for Biochemistry and Molecular Biology, International Narcotics Research Conference (Executive Committee 1995-1998 and 2010-present; President 2006-2010), New York Academy of Sciences (Biological Pharmacology Discussion Group Steering Committee 2000-2003 and 2009-present), Society for Neuroscience (Committee on the Development of Women's Careers in Neuroscience 2003-2004; Committee of Women in Neuroscience 2004-2006), Winter Conference in Brain Research (Program Committee 2011-present). Editorial Activities – Editorial Board, *Journal of Biological Chemistry;* Editorial Board, *Biochemical Journal.*

NOMINEE FOR SECRETARY/TREASURER-ELECT
Division for Neuropharmacology

Susan L. Ingram Osborn

Associate Professor, Department of Neurological Surgery, Oregon Health & Science University (OHSU), Portland, Oregon

Education: A.B. (1990, Neuroscience), Bowdoin College, Brunswick ME; Ph.D. (1995, Department of Pharmacology/Neuroscience Program), Oregon Health & Science University, Portland OR.

Professional Experience: Human Frontiers Postdoctoral Fellow (1996-1998), Department of Pharmacology, University of Sydney, Sydney, Australia; Postdoctoral Fellow (1998-2002), Research Assistant Professor (2002-2003), Vollum Institute, OHSU; Assistant Professor (2003-2010), Associate Professor (2010-2011), Department of Psychology, Washington State University Vancouver; Associate Professor (2011-present), Department of Neurological Surgery, OHSU.

Research Interests: My research is focused on understanding neuronal mechanisms of synaptic plasticity in response to acute and long-term exposure to drugs of abuse. I am particularly interested in how drugs of abuse alter pain pathways in the central nervous system.

Activities:
ASPET: Member of ASPET since 2007. Divisions – Neuropharmacology (Executive Committee 2011-present), Behavioral Pharmacology, Molecular Pharmacology. Committees – Committee on Women in Pharmacology (2010-present).
Other: Member - International Narcotics Research Conference (INRC) (Executive Committee Member 2010-present; Co-organizer 2009 conference), International Association for the Study of Pain, Society for Neuroscience, Sigma Xi.

NOMINEE FOR SECRETARY/TREASURER-ELECT
Division for Neuropharmacology

Ping-Yee Law

Professor, Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota

Education: B.A. (1969, Chemistry), Luther College, Decorah, IA; Ph.D. (1973, Biochemistry), University of Illinois-Champaign-Urbana.

Professional Experience: Research Fellow (1973-1975), CVRI, Research Fellow (1975-1978), Assistant Research Pharmacologist (1978-1985), Department of Pharmacology, Associate Research Pharmacologist (1985-1988), Department of Psychiatry, University of California-San Francisco; Associate Professor (1988-1997), Professor (1997-present), Department of Pharmacology, University of Minnesota. Visiting Professor (2004), Hatos Center for Neuropharmacology, University of

California-Los Angeles; Visiting Professor (2006-2010), Instituto de Neuroscience de Castilla Y Leon, Universidad de Salamanca, Salamanca, Spain.

Research Interests: The overall focus of Dr. Law's research is on the cellular regulation of opioid receptor signaling, focusing on the mechanisms and the *in vivo* consequences of biased agonism. His studies involve the agonist-dependent miRNA-mediated regulation of adult neurogenesis and its roles in drug addiction processes.

Activities:
ASPET: Member of ASPET since 1981. Divisions – Neuropharmacology, Molecular Pharmacology. Editorial Activities – Editorial Board for *Molecular Pharmacology.*
Other: Member – American Society for Biochemistry and Molecular Biology, Society of Chinese Biologists in America, Society for Neuroscience.

Division for Toxicology

NOMINEE FOR CHAIR-ELECT
Division for Toxicology

Rick G. Schnellmann

Eminent Scholar, Professor and Chair, Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina

Education: B.S. (1980, Pharmacy), St. Louis College of Pharmacy; PhD (1984, Pharmacology and Toxicology), University of Arizona Tucson, AZ.

Professional Experience: Postdoctoral Fellow (1984-1986), Department of Physiology, Duke University; Assistant Professor (1986-1990), Associate Professor (1990-1994), Department of Physiology and Pharmacology, University of Georgia; Professor (1994-2001); Professor, Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences; Professor and Chair (2001-present), Director of Center for Drug Discovery in Center (2004-present), Director, Center for Medication Safety and Efficacy (2005-2010), Eminent Scholar (2007-present), Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina.

Research Interest: Determine the role of phospholipases and calpain 10 in mitochondrial function and injury following oxidant/toxicant exposure, particularly in the kidney. Determine the role of mitochondria in initiation and recovery from acute kidney injury. Identify new drugs that stimulate mitochondrial biogenesis as a therapeutic treatment for acute kidney injury, liver dysfunction, and myocardial infarction.

Activities:
ASPET: Member of ASPET since 1984. Divisions – Toxicology (Secretary/Treasurer 1999-2000, Executive Committee 1998-2001); Drug Discovery, Development and Regulatory Affairs; Integrative Systems, Translational and Clinical Pharmacology; Molecular Pharmacology. Committees –

Graduate Recruitment and Education Committee (1999-2002). Editorial Activities - Associate Editor (1998-2003) and Editor (2004-2009) *Journal of Pharmacology and Experimental Therapeutics*; Board of Publications Trustees (2004-2009).
Other: Member – American Physiological Society, Society of Toxicology (ad hoc Tox 90s Educational Issues Task Force 1991-1993, Finance Committee 1993-1996, Chair, Education Committee 1997-2000, Treasurer 2000-2003). Editorial Activities - Editorial Board, *American Journal of Physiology.*

NOMINEE FOR CHAIR-ELECT
Division for Toxicology



Jeffrey L. Staudinger

Associate Professor, Department of Pharmacology and Toxicology, University of Kansas School of Pharmacy, Lawrence, Kansas

Education: B.S. (1987, Biology), Nebraska Wesleyan University; M.S. (1994, Biochemistry and Molecular Biology), Ph.D. (1996, Biochemistry and Molecular Biology), University of Texas Graduate School of Biomedical Sciences.

Professional Experience: Postdoctoral Research Fellow (1996-1999), Nuclear Receptor Group, GlaxoWellcome Research, Research Triangle Park, NC; Senior Postdoctoral Fellow (2000-2001), Department of Pharmacology, Toxicology and Experimental Therapeutics, University of Kansas Medical Center, Kansas City; Assistant Professor (2001-2006), Associate Professor (2006-present), Department of Pharmacology and Toxicology, University of Kansas School of Pharmacy, Lawrence.

Research Interests: Dr. Staudinger's laboratory is interested in basic regulatory mechanisms in toxicology. He works primarily with mice and tissue culture as model systems to investigate two major questions. (1) What role do ligand-activated transcription factors play in regulating xenobiotic homeostasis? (2) What signal transduction pathways interface with ligand-activated transcription factors in mediating xenobiotic homeostasis.

Activities:
ASPET: Member of ASPET since 2004. Divisions – Toxicology, Drug Metabolism, Molecular Pharmacology.
Other: Member – AAAS, American Society for Biochemistry and Molecular Biology, International Society for the Study of Xenobiotics. Editorial activities – Editorial Advisory Board for *Molecular Pharmaceutics*.

NOMINEE FOR SECRETARY/TREASURER-ELECT
Division for Toxicology

Laura James

Professor, Department of Pediatrics, University of Arkansas for Medical Sciences and Section Chief, Clinical Pharmacology and Toxicology, Arkansas Children's Hospital, Little Rock, Arkansas

Education: B.S. (1985, Biology), Furman University; Doctor of Medicine, (1989), University of South Carolina School of Medicine, Columbia, SC.

Professional Experience: Pediatrics Residency (1989-1992), University of Arkansas for Medical Sciences/Arkansas Children's Hospital; Pediatric Emergency Medicine Fellow (1992-1994), University of Alabama at Birmingham/The Children's Hospital of Alabama; Pediatric Clinical Pharmacology/ Toxicology Fellow (1994-1996), Faculty (1996-present), Department of Pediatrics, University of Arkansas for Medical Sciences/Arkansas Children's Hospital; Adjunct Professor (2002-present), Department of Pharmacology, University of Arkansas for Medical Sciences.

Research Interests: Dr. James studies mechanisms of acetaminophen toxicity and repair in clinical and experimental models. She also studies acetaminophen toxicity in children and adolescents and has funded research through a small business grant to develop a point-of-care test for acetaminophen protein adducts.

Activities:
ASPET: Member of ASPET since 2006. Divisions – Toxicology; Integrative Systems, Translational and Clinical Pharmacology (Executive Committee member 2007-2010 of then Clinical Pharmacology, Pharmacogenomics and Translational Medicine Division).
Other: Member – American Society for Clinical Pharmacology and Therapeutics. Editorial activities – Associate Editor for *Clinical Pharmacology and Therapeutics.*

NOMINEE FOR SECRETARY/TREASURER-ELECT
Division for Toxicology

Kenneth E. McMartin

Professor of Pharmacology, Toxicology & Neuroscience, Louisiana State University Health Sciences Center, Shreveport, Louisiana

Education: B.A. (1973, Chemistry), Coe College, Cedar Rapids, IA; Ph.D. (1977, Pharmacology), University of Iowa, Iowa City, IA.

Professional Experience: Postdoctoral Fellow (1977-1978), Department of Clinical Chemistry, Huddinge University Hospital, Karolinska Institute, Sweden; Assistant Research Scientist (1979-1980), Department of

Pharmacology, University of Iowa; Assistant Professor (1980-1984), Associate Professor (1984-1990), Professor (1990-present), Department of Pharmacology, Toxicology & Neuroscience, Louisiana State University Health Sciences Center-Shreveport; Visiting Associate Professor (1989-1990), Department of Pathology and Laboratory Medicine, Medical University of South Carolina; Visiting Professor (2002-2003), Department of Biochemistry and Molecular Biology, University of Minnesota-Duluth.

Research Interests: 1) The mechanism of the renal toxicity of ethylene glycol, in particular the intracellular mechanisms for the cytotoxicity of oxalate; 2) The mechanisms for ethanol-induced folate deficiency, in particular the mechanisms by which ethanol inhibits the reabsorptive transport of folate by renal proximal tubule cells; 3) The mechanism for the renal toxicity of diglycolic acid, which is the toxic metabolite of diethylene glcyol

Activities:
ASPET: Member of ASPET since 1984. Divisions – Toxicology, Drug Metabolism.
Other: Member – Society of Toxicology (Judge of Graduate Student Awards, Mechanisms Specialty Section, 1989, 2010; Committee for K-12 Education, 2003-2006, chair 2005-2006; founding member and interim vice-president of the Clinical and Translational Toxicology Specialty Section, 2011); South Central Regional Chapter SOT (Councilor 2002-2006, President 2004-2005); Research Society on Alcoholism; American Academy of Clinical Toxicology (Board of Trustees, 2010-2011; Chair, Research Awards Committee, 2010-2011); American Society for Nutritional Sciences.

ELECTION CLOSES AT 5:00 PM ON JANUARY 27, 2012

American Society for Pharmacology and Experimental Therapeutics
9650 Rockville Pike, Bethesda, Maryland 20814-3995 ◆ 301-634-7060 ◆ 301-634-7061 fax
info@aspet.org www.aspet.org